Multicentric randomized phase 2 immunotherapy with CpG-ODN [CPG 2216] in malignant glioblastoma
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2012
At a glance
- Drugs CPG 2216 (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 01 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Nov 2005 New trial record.